Eric Patzer - May 4, 2023 Form 4 Insider Report for Aridis Pharmaceuticals, Inc. (ARDS)

Role
Executive Chairman, Director
Signature
/s/ Eric Patzer
Stock symbol
ARDS
Transactions as of
May 4, 2023
Transactions value $
$0
Form type
4
Date filed
6/15/2023, 05:16 PM
Previous filing
Dec 7, 2022
Next filing
Sep 19, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARDS Common Stock Options Exercise +12K +1.71% 714K Jun 5, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARDS Stock Options Award $0 +30K +25.67% $0.00 147K May 4, 2023 Common Stock 30K $0.16 Direct F1
transaction ARDS Restricted Stock Units Options Exercise -12K -50% 12K Jun 5, 2023 Common Stock 12K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 12,000 shares of Common Stock vested on June 5, 2023 and 12,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.